Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Inclusion Criteria: * Participants aged ≥18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local treatment practices and product label for the first time. * Female participants of childbearing potential must agree to use contraception while taking filgotinib as per product label. * Participants must be willing and able to use an electronic device to complete the study PROs. * Participant must sign and date the Informed Consent Form (ICF) before enrollment into the study. Exclusion Criteria: * Participation in any interventional or non-interventional study without prior approval from the Medical Lead. This does not preclude inclusion of participants enrolled to national registries. * Female participant is pregnant or intending to become pregnant while taking filgotinib.